Cargando…

Estimated Life Expectancy Without Recurrent Cardiovascular Events in Patients With Vascular Disease: The SMART‐REACH Model

BACKGROUND: In patients with vascular disease, risk models may support decision making on novel risk reducing interventions, such as proprotein convertase subtilisin/kexin type 9 inhibitors or anti‐inflammatory agents. We developed and validated an innovative model to estimate life expectancy withou...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kaasenbrood, Lotte, Bhatt, Deepak L., Dorresteijn, Jannick A.N., Wilson, Peter W.F., D'Agostino, Ralph B., Massaro, Joseph M., van der Graaf, Yolanda, Cramer, Maarten J.M., Kappelle, L. Jaap, de Borst, Gert J., Steg, Ph. Gabriel, Visseren, Frank L. J.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2018
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6201391/ https://www.ncbi.nlm.nih.gov/pubmed/30369323 http://dx.doi.org/10.1161/JAHA.118.009217

Ejemplares similares

The influence of baseline risk on the relation between HbA1c and risk for new cardiovascular events and mortality in patients with type 2 diabetes and symptomatic cardiovascular disease
por: Bots, Sophie H., et al.
Publicado: (2016)

Cost‐Effectiveness of Intensifying Lipid‐Lowering Therapy With Statins Based on Individual Absolute Benefit in Coronary Artery Disease Patients
por: Stam‐Slob, Manon C., et al.
Publicado: (2017)

Would treatment decisions about secondary prevention of CVD based on estimated lifetime benefit rather than 10-year risk reduction be cost-effective?
por: Berkelmans, Gijs F. N., et al.
Publicado: (2020)

Communicating personalised statin therapy-effects as 10-year CVD-risk or CVD-free life-expectancy: does it improve decisional conflict? Three-armed, blinded, randomised controlled trial
por: Jaspers, Nicole E M, et al.
Publicado: (2021)

Use of lipid-lowering therapy after ischaemic stroke and expected benefit from intensification of treatment
por: Gynnild, Mari Nordbø, et al.
Publicado: (2022)

Variation in minimum desired cardiovascular disease-free longevity benefit from statin and antihypertensive medications: a cross-sectional study of patient and primary care physician perspectives
por: Jaspers, Nicole E M, et al.
Publicado: (2018)

The daily 10 kcal expenditure deficit: a before-and-after study on low-cost interventions in the work environment
por: Dorresteijn, Johannes A N, et al.
Publicado: (2013)

Physical exercise volume, type, and intensity and risk of all-cause mortality and cardiovascular events in patients with cardiovascular disease: a mediation analysis
por: Bonekamp, Nadia E, et al.
Publicado: (2023)

Lifestyle changes and kidney function: A 10‐year follow‐up study in patients with manifest cardiovascular disease
por: Østergaard, Helena Bleken, et al.
Publicado: (2022)

External applicability of SGLT2 inhibitor cardiovascular outcome trials to patients with type 2 diabetes and cardiovascular disease
por: Smidt, Lisanne C. A., et al.
Publicado: (2021)

End-stage kidney disease in patients with clinically manifest vascular disease; incidence and risk factors: results from the UCC-SMART cohort study
por: Østergaard, Helena Bleken, et al.
Publicado: (2021)

Modifiable risk factors control and its relationship with 1 year outcomes after coronary artery bypass surgery: insights from the REACH registry
por: Mehta, Rajendra H., et al.
Publicado: (2008)

Identifying treatment response to antihypertensives in patients with obesity-related hypertension
por: Schrover, Ilse M., et al.
Publicado: (2017)

Added value of cardiovascular calcifications for prediction of recurrent cardiovascular events and cardiovascular interventions in patients with established cardiovascular disease
por: van ’t Klooster, Cilie C., et al.
Publicado: (2021)

Physical Activity and Characteristics of the Carotid Artery Wall in High‐Risk Patients—The SMART (Second Manifestations of Arterial Disease) Study
por: Boss, H. Myrthe, et al.
Publicado: (2017)

Extracellular vesicle protein levels are related to brain atrophy and cerebral white matter lesions in patients with manifest vascular disease: the SMART-MR study
por: Kanhai, Danny A, et al.
Publicado: (2014)

Thyroid-stimulating hormone levels in the normal range and incident type 2 diabetes mellitus
por: de Vries, T. I., et al.
Publicado: (2018)

Low-grade inflammation as a risk factor for cardiovascular events and all-cause mortality in patients with type 2 diabetes
por: Sharif, Shahnam, et al.
Publicado: (2021)

Misinterpretation of ischaemic infarct location in relationship to the cerebrovascular territories
por: Hartkamp, Nolan S, et al.
Publicado: (2016)

The reduction in cardiovascular risk in REDUCE-IT is due to eicosapentaenoic acid in icosapent ethyl
por: Steg, Ph Gabriel, et al.
Publicado: (2021)

Broadening the reach of Health Expectations
por: Chew‐Graham, Carolyn A.
Publicado: (2017)

Risk Stratification in Patients with Ischemic Stroke and Residual Cardiovascular Risk with Current Secondary Prevention
por: Gynnild, Mari Nordbø, et al.
Publicado: (2021)

Risk score to predict serious bleeding in stable outpatients with or at risk of atherothrombosis
por: Ducrocq, Gregory, et al.
Publicado: (2010)

Estimating treatment effects for individual patients based on the results of randomised clinical trials
por: Dorresteijn, Johannes A N, et al.
Publicado: (2011)

Determinants of leptomeningeal collateral flow in stroke patients with a middle cerebral artery occlusion
por: van Seeters, Tom, et al.
Publicado: (2016)

Personalizing treatment in end-stage kidney disease: deciding between haemodiafiltration and haemodialysis based on individualized treatment effect prediction
por: van Kruijsdijk, Rob C M, et al.
Publicado: (2022)

Cohort profile: the Utrecht Cardiovascular Cohort–Second Manifestations of Arterial Disease (UCC-SMART) Study–an ongoing prospective cohort study of patients at high cardiovascular risk in the Netherlands
por: Castelijns, Maria C, et al.
Publicado: (2023)

The Role of Haptic Expectations in Reaching to Grasp: From Pantomime to Natural Grasps and Back Again
por: Whitwell, Robert L., et al.
Publicado: (2020)

Mediation analysis of the relationship between type 2 diabetes and cardiovascular events and all‐cause mortality: Findings from the SMART cohort
por: Sharif, Shahnam, et al.
Publicado: (2019)

Estimation of recurrent atherosclerotic cardiovascular event risk in patients with established cardiovascular disease: the updated SMART2 algorithm
por: Hageman, Steven H J, et al.
Publicado: (2022)

The REACH 2010 Logic Model: An Illustration of Expected Performance
por: Tucker, Pattie, et al.
Publicado: (2005)

Preventing Deep Vein Thrombosis After Stroke: Strategies and Recommendations
por: Kappelle, L. Jaap
Publicado: (2011)

Screen-detected abnormal ankle brachial index: A risk indicator for future cardiovascular morbidity and mortality in patients with manifest cardiovascular disease
por: Jagt, Vivianne L., et al.
Publicado: (2022)

Cardiovascular risk factor treatment targets and renal complications in high risk vascular patients: a cohort study
por: Selvarajah, Sharmini, et al.
Publicado: (2011)

Platelet aggregation inhibitor prescription for newly diagnosed peripheral arterial disease in the Netherlands: a cohort study
por: Brand, Aarent RT, et al.
Publicado: (2021)

Completeness of the circle of Willis and risk of ischemic stroke in patients without cerebrovascular disease
por: van Seeters, Tom, et al.
Publicado: (2015)

Angina and Future Cardiovascular Events in Stable Patients With Coronary Artery Disease: Insights From the Reduction of Atherothrombosis for Continued Health (REACH) Registry
por: Eisen, Alon, et al.
Publicado: (2016)

Intervention versus standard medical treatment in patients with symptomatic occlusion of the internal carotid artery: a randomised oxygen-15 PET study
por: Persoon, Suzanne, et al.
Publicado: (2013)

Three-year follow-up and event rates in the international REduction of Atherothrombosis for Continued Health Registry
por: Alberts, Mark J., et al.
Publicado: (2009)

Pioglitazone and the secondary prevention of cardiovascular disease. A meta-analysis of randomized-controlled trials
por: de Jong, Marit, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_6pt4m1duldo4od2j4f13vg40mh